Top-Rated Stocks NASDAQ:ARGX argenx - ARGX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding argenx SE Please log in to your account or sign up in order to add this asset to your watchlist. $370.44 -0.51 (-0.14%) (As of 02/6/2023 01:18 PM ET) Add Compare Share Share Today's Range$367.17▼$378.1150-Day Range$369.42▼$403.6552-Week Range$256.44▼$407.93Volume133,884 shsAverage Volume223,820 shsMarket Capitalization$20.52 billionP/E RatioN/ADividend YieldN/APrice Target$453.23 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media argenx MarketRank™ ForecastAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside20.8% Upside$453.23 Price TargetShort InterestHealthy1.40% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($15.54) to ($9.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector333rd out of 1,025 stocksBiological Products, Except Diagnostic Industry57th out of 168 stocks 3.5 Analyst's Opinion Consensus Ratingargenx has received a consensus rating of Buy. The company's average rating score is 2.93, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $453.23, argenx has a forecasted upside of 20.8% from its current price of $375.32.Amount of Analyst Coverageargenx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.40% of the outstanding shares of argenx have been sold short.Short Interest Ratio / Days to Coverargenx has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in argenx has recently decreased by 6.73%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yieldargenx does not currently pay a dividend.Dividend Growthargenx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARGX. Previous Next 2.4 News and Social Media Coverage News Sentimentargenx has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for argenx this week, compared to 3 articles on an average week.Search Interest4 people have searched for ARGX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added argenx to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, argenx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.43% of the stock of argenx is held by insiders.Percentage Held by Institutions57.29% of the stock of argenx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for argenx are expected to grow in the coming year, from ($15.54) to ($9.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of argenx is -21.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of argenx is -21.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratioargenx has a P/B Ratio of 7.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About argenx (NASDAQ:ARGX) Stockargenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.Read More Receive ARGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter. Email Address ARGX Stock News HeadlinesFebruary 1, 2023 | americanbankingnews.comargenx SE (NASDAQ:ARGX) Sees Large Decline in Short InterestJanuary 31, 2023 | americanbankingnews.comargenx SE (NASDAQ:ARGX) to Post FY2022 Earnings of ($15.03) Per Share, Jefferies Financial Group ForecastsFebruary 6, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 29, 2023 | americanbankingnews.comFY2025 Earnings Forecast for argenx SE Issued By Jefferies Financial Group (NASDAQ:ARGX)January 28, 2023 | americanbankingnews.comCowen Increases argenx (NASDAQ:ARGX) Price Target to $458.00January 28, 2023 | americanbankingnews.comAnalysts Set argenx SE (NASDAQ:ARGX) Price Target at $452.18January 28, 2023 | americanbankingnews.comWilliam Blair Analysts Lift Earnings Estimates for argenx SE (NASDAQ:ARGX)January 27, 2023 | finance.yahoo.comargenx Receives Notification of PDUFA Date Extension for SC EfgartigimodFebruary 6, 2023 | Investing Trends (Ad)"We need batteries. Literally everywhere."Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense." January 16, 2023 | finance.yahoo.comargenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive DirectorJanuary 3, 2023 | finance.yahoo.comargenx to Present at 41st Annual J.P. Morgan Healthcare ConferenceDecember 12, 2022 | finance.yahoo.comargenx Appoints Ana Cespedes to Board of DirectorsNovember 30, 2022 | markets.businessinsider.comArgenx To Acquire FDA Priority Review Voucher - Quick Facts November 22, 2022 | finance.yahoo.comArgenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA ReviewNovember 22, 2022 | finance.yahoo.comargenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority ReviewNovember 22, 2022 | markets.businessinsider.comArgenx : FDA Accepts BLA For SC Efgartigimod In Generalized Myasthenia Gravis With Priority Review November 15, 2022 | finance.yahoo.comShould You Invest in argenx SE (ARGX)?November 2, 2022 | finance.yahoo.comWill argenx SE (ARGX) Deliver Solid Performance in Near-Term?October 27, 2022 | finance.yahoo.comargenx Reports Third Quarter 2022 Financial Results and Provides Business UpdateOctober 26, 2022 | finance.yahoo.comWhy Earnings Season Could Be Great for argenx (ARGX)October 20, 2022 | finance.yahoo.comargenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022October 18, 2022 | benzinga.com7 Analysts Have This to Say About argenx - argenx (NASDAQ:ARGX) - BenzingaOctober 17, 2022 | seekingalpha.comImmunovant Stock: Capitalizing On Fast Growing FcRn Space With Novel Asset (NASDAQ:IMVT) - Seeking AlphaOctober 14, 2022 | finance.yahoo.comThrombocytopenia Market Insights, Epidemiology and Market Forecasts, 2032 - Yahoo FinanceOctober 6, 2022 | finance.yahoo.comGeneralized Myasthenia Gravis Pipeline Assessment Unveils Top Contenders to Challenge Current Market Biologics - New Spherix Report - Yahoo FinanceOctober 1, 2022 | reuters.comARGX.O - argenx SE - ADR | Stock Price & Latest News | ReutersSeptember 23, 2022 | investors.comTom O'Halloran: Are We On The Cusp Of A Bull Market? - Video - IBD - Investor's Business DailySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ARGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter. Email Address ARGX Company Calendar Last Earnings10/27/2021Today2/06/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARGX CUSIPN/A CIK1697862 Webwww.argenx.com Phone(176) 303-0488FaxN/AEmployees650Year FoundedN/APrice Target and Rating Average Stock Price Forecast$453.23 High Stock Price Forecast$480.00 Low Stock Price Forecast$420.00 Forecasted Upside/Downside+22.3%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($17.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-408,270,000.00 Net Margins-295.08% Pretax MarginN/A Return on Equity-66.04% Return on Assets-59.60% Debt Debt-to-Equity RatioN/A Current Ratio11.07 Quick Ratio10.56 Sales & Book Value Annual Sales$539.42 million Price / Sales38.05 Cash FlowN/A Price / Cash FlowN/A Book Value$49.05 per share Price / Book7.55Miscellaneous Outstanding Shares55,400,000Free Float54,050,000Market Cap$20.52 billion OptionableOptionable Beta0.73 Key ExecutivesTim van HauwermeirenChief Executive Officer & Executive DirectorR. Keith WoodsChief Operating OfficerKarl GubitzChief Financial OfficerHans J. W. de HaardChief Scientific OfficerLuc TruyenChief Medical OfficerKey CompetitorsSeagenNASDAQ:SGENBio-TechneNASDAQ:TECHQiagenNYSE:QGENNeurocrine BiosciencesNASDAQ:NBIXRepligenNASDAQ:RGENView All CompetitorsInsiders & InstitutionsParallel Advisors LLCBought 37 shares on 2/6/2023Ownership: 0.001%EFG Asset Management North America Corp.Sold 1,566 shares on 2/3/2023Ownership: 0.028%TobamBought 12,027 shares on 2/2/2023Ownership: 0.053%SG Americas Securities LLCBought 10,440 shares on 2/2/2023Ownership: 0.033%Profund Advisors LLCSold 992 shares on 2/2/2023Ownership: 0.002%View All Institutional Transactions ARGX Stock - Frequently Asked Questions Should I buy or sell argenx stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARGX shares. View ARGX analyst ratings or view top-rated stocks. What is argenx's stock price forecast for 2023? 15 Wall Street analysts have issued 1 year price targets for argenx's shares. Their ARGX share price forecasts range from $420.00 to $480.00. On average, they expect the company's stock price to reach $453.23 in the next year. This suggests a possible upside of 22.2% from the stock's current price. View analysts price targets for ARGX or view top-rated stocks among Wall Street analysts. How have ARGX shares performed in 2023? argenx's stock was trading at $378.83 at the beginning of the year. Since then, ARGX stock has decreased by 2.1% and is now trading at $370.95. View the best growth stocks for 2023 here. Are investors shorting argenx? argenx saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 777,900 shares, a decline of 6.7% from the December 31st total of 834,000 shares. Based on an average trading volume of 252,000 shares, the short-interest ratio is presently 3.1 days. View argenx's Short Interest. When is argenx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our ARGX earnings forecast. How were argenx's earnings last quarter? argenx SE (NASDAQ:ARGX) released its quarterly earnings data on Wednesday, October, 27th. The company reported ($4.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.48) by $0.38. The company earned $7.11 million during the quarter, compared to analysts' expectations of $20 million. argenx had a negative net margin of 295.08% and a negative trailing twelve-month return on equity of 66.04%. During the same period last year, the company earned ($3.96) EPS. What other stocks do shareholders of argenx own? Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT). When did argenx IPO? (ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is argenx's stock symbol? argenx trades on the NASDAQ under the ticker symbol "ARGX." Who are argenx's major shareholders? argenx's stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.24%), New York State Common Retirement Fund (0.21%), Allspring Global Investments Holdings LLC (0.13%), Bank of Montreal Can (0.12%), Tobam (0.05%) and Mckinley Capital Management LLC Delaware (0.04%). How do I buy shares of argenx? Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is argenx's stock price today? One share of ARGX stock can currently be purchased for approximately $370.95. How much money does argenx make? argenx (NASDAQ:ARGX) has a market capitalization of $20.55 billion and generates $539.42 million in revenue each year. The company earns $-408,270,000.00 in net income (profit) each year or ($17.19) on an earnings per share basis. How many employees does argenx have? The company employs 650 workers across the globe. How can I contact argenx? argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The official website for the company is www.argenx.com. The company can be reached via phone at (176) 303-0488 or via email at info@argenx.com. This page (NASDAQ:ARGX) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.